pH-Responsive Pegylated Chitosan Nanocarrier Developed for Targeted Delivery of 17-AAG in HER2-Positive Breast Cancer Treatment

Researchers have developed a pH-responsive pegylated chitosan nanocarrier designed for the targeted delivery of 17-AAG, a heat shock protein 90 (Hsp90) inhibitor, in HER2-positive breast cancer treatment. The study also explored the potential for synergistic therapy using this nanocarrier system. The findings indicate that this approach may enhance drug delivery efficiency and improve therapeutic outcomes by targeting cancer cells more effectively.

The research focused on creating a nanocarrier capable of responding to the acidic environment typically found in tumor tissues. By utilizing pegylated chitosan, the team aimed to improve stability and biocompatibility while ensuring precise drug release at the target site. The study demonstrated that the nanocarrier successfully delivered 17-AAG to HER2-positive breast cancer cells, showing promise in reducing tumor growth. Additionally, researchers investigated its potential for combination therapy, suggesting that it could work alongside other treatments to achieve enhanced therapeutic effects. Further studies are expected to evaluate its clinical applications and safety profile.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Express Scripts Takes Lead as Top 3 PBMs Process Nearly 80% of Prescription Claims in 2024 TurboFil Introduces MediFil Cart with Servo-Controlled Ceramic Vial Filling for Precision Dosing Charities Report Rising Demand for Services Over Past Year According to CAF Study Chung-Ang University Researchers Develop Dual-Level Interlayer Design to Enhance Lithium-Sulfur Battery Performance

Author

GOAI